PDF icon Download PDF
Open Access
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2021; 42(04): 339-345
DOI: 10.1055/s-0041-1731856
Original Article

Adult Soft Tissue Sarcoma: A Prospective Observational Real-World Data

Shivashankara Mathighatta Shivarudraiah
1   Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Referral Centre, New Delhi, India
,
Sundaram Viswanath
2   Department of Medical Oncology, Army Hospital Research & Referral, New Delhi, India
,
Suresh Pandalanghat
2   Department of Medical Oncology, Army Hospital Research & Referral, New Delhi, India
,
Dharmesh Soneji
2   Department of Medical Oncology, Army Hospital Research & Referral, New Delhi, India
,
Manish Kumar
2   Department of Medical Oncology, Army Hospital Research & Referral, New Delhi, India
,
Amol Patel
2   Department of Medical Oncology, Army Hospital Research & Referral, New Delhi, India
,
Bupesh Guleria
3   Department of Medical Oncology, Basavatarakam Indo-American Cancer Institute and Research Centre, India
,
Nikhil Pathi
2   Department of Medical Oncology, Army Hospital Research & Referral, New Delhi, India
,
Rahul Sud
2   Department of Medical Oncology, Army Hospital Research & Referral, New Delhi, India
,
Abhishek Pathak
2   Department of Medical Oncology, Army Hospital Research & Referral, New Delhi, India
,
Anvesh Rathore
2   Department of Medical Oncology, Army Hospital Research & Referral, New Delhi, India
› Author Affiliations
› Further Information
Also available ateRef
  Permissions and Reprints
Preview

Abstract

Introduction There is a lacuna of prospective studies on soft tissue sarcoma (STS) from the Indian subcontinent in published literature.

Objectives We conducted this study to describe the clinical profile and outcomes of STS in North India.

Materials and Methods This is a single-center, prospective, observational study conducted from October 2017 to September 2019. All consecutive patients aged ≥18 years with histopathological diagnosis of STS were enrolled. The study end points included overall response rate, progression-free survival (PFS), and overall survival (OS).

Results A total of 140 patients were included with a median duration of follow-up of 14 months (range: 1–25 months). The median age of patients was 45 years. The median duration of symptoms before diagnosis was 5 months (range: 1–18 months). The most common histopathologic subtype was undifferentiated pleomorphic STS (22%). Of 105 localized patients, 21 received neoadjuvant therapy with external beam radiotherapy and/or doxorubicin-based chemotherapy and reported partial response in 38% (8/21) of the patients; the remaining 62% (13/21) of the patients had stable disease. Neoadjuvant therapy resulted in nonsignificantly higher complete resection rates with relative risk of 2.37 (p = 0.19). Of the remaining 35 metastatic STS patients, 31 received chemotherapy and reported partial response in 39.1% (n = 9/23), stable disease in 30.4% (n = 7/23), and disease progression in 30.4% (n = 7/23) of the patients. For localized STS patients, 1-year disease-free survival (DFS) and OS rates were 87.6 ±3.5 and 95.3 ± 2.3%, respectively. The median OS for metastatic STS patients was 23.90 months (95% confidence interval [CI]: 7.43–40.36). Among metastatic STS, median OS was not reached for those who underwent curative resection versus 12.66 months (95% CI: 9.28–16.04) for those who received systemic therapy alone.

Conclusion Median age of 45 years is a decade earlier than seen in the Western population. Neoadjuvant therapy improved complete resection rates, though it was statistically nonsignificant. Curative resection among metastatic STS patients improves survival.

Keywords

survival outcomes - developing countries - epidemiology - India - real-world data - soft tissue sarcoma - STS


Publication History

Article published online:
25 November 2021

© 2021. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India